This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other sulfur-bearing amino acid disorders — Cystathioninuria / Methioninemia / Hyperhomocysteinemia기타유황아미노산장애

Contents and key points
ItemDetails
A. Classification codesICD-10: E72.1 (other sulfur-bearing amino acid disorders) | Special Copayment Reduction: V117 (rare disease)
B. SynonymsCystathioninuria, Methioninemia / Hypermethioninemia, Hyperhomocysteinemia, CBS deficiency, MAT I/III deficiency, GNMT deficiency, BHMT deficiency, MTHFR deficiency, Sulfur amino acid disorders
C. Adult onsetModerate to high likelihood of first presenting in adulthood — mild hyperhomocysteinemia (including the MTHFR 677TT polymorphism) is commonly first discovered in adulthood through thromboembolism or cardiovascular events; cystathioninuria and methioninemia are mostly asymptomatic and are found on newborn screening or incidental metabolic testing; moderate to severe CBS deficiency is diagnosed in childhood by ectopia lentis and skeletal abnormalities, but mild forms may first be diagnosed in young to middle adulthood by a thrombotic event.
1. History1932 du Vigneaud elucidates the methionine sulfur metabolic pathway → 1955 first description of homocystinuria (Gerritsen) → 1963 identification of CBS deficiency (Mudd) → 1970s description of methionine adenosyltransferase deficiency → 1988 study of the MTHFR thermolabile variant and cardiovascular risk → 1990s introduction of tandem mass spectrometry newborn screening.
2. CausesDeficiency of enzymes in the metabolic pathway of sulfur-containing amino acids (methionine → homocysteine → cystathionine → cysteine). Variants in the CBS (cystathionine β-synthase), CTH (cystathionase), MAT I/III, GNMT, MTHFR, BHMT, MTR and MTRR genes.
3. GeneticsAutosomal recessive inheritance (CBS, CTH, MAT, GNMT, etc.). The MTHFR 677C>T polymorphism is a recessive predisposition, but when homozygous it causes mild functional reduction. Multiple genes cooperate in the same pathway, so the phenotype is varied.
4. General epidemiologyCBS deficiency (classical homocystinuria): about 1 in 200,000–350,000. Cystathioninuria: about 1 in 14,000 (newborn screening). MTHFR 677TT homozygosity: about 10–15% of Caucasians, about 9–12% of Koreans.
5. PathophysiologyHomocysteine accumulation → vascular endothelial damage, increased oxidative stress, promotion of thrombotic tendency. Methionine excess → S-adenosylmethionine (SAM) imbalance → impaired methylation reactions. Cystathionine accumulation → mostly asymptomatic but may affect neurodevelopment.
6. SymptomsCBS deficiency: ectopia lentis, Marfanoid skeleton, intellectual disability, thromboembolism. Hyperhomocysteinemia: myocardial infarction, stroke, deep vein thrombosis. Methioninemia: mostly asymptomatic, bad breath odor. Cystathioninuria: mostly asymptomatic.
7. SignsInferior lens dislocation (CBS deficiency), scoliosis, long limbs and pectus excavatum (Marfanoid), thrombophlebitis or arterial thrombosis. Plasma amino acids: elevated homocysteine and methionine, or elevated cystathionine.
8. ScreeningNewborn screening: measurement of blood methionine and homocystine by tandem mass spectrometry (MS/MS). High-risk groups: plasma total homocysteine (tHcy), plasma amino acid analysis. MTHFR genotype testing.
9. DiagnosisMeasurement of plasma total homocysteine (tHcy), plasma and urine amino acid analysis (homocystine, cystathionine, methionine), measurement of CBS, CTH and MAT enzyme activity (liver, red blood cells), genetic panel testing. Pyridoxine challenge test (assessment of B6 responsiveness in CBS deficiency).
10. TreatmentB6-responsive CBS deficiency: high-dose pyridoxine. Non-responsive: methionine-restricted diet + cystine supplementation, betaine, folate/B12. Hyperhomocysteinemia: folate, B6 and B12 supplementation. Methioninemia: low-methionine diet. Thrombosis prevention: anticoagulants.
11. PrognosisWith early treatment, thrombotic and neurological complications of CBS deficiency can be prevented. The B6-responsive form has a good prognosis. Cystathioninuria and simple methioninemia have a benign course. Untreated hyperhomocysteinemia increases the risk of early cardiovascular disease.
12. PreventionEarly diagnosis by newborn screening. Adequate intake of folate and B vitamins. Genetic counseling and carrier testing if there is a family history. Anticoagulation management for thrombotic risk groups. Homocysteine monitoring during pregnancy in women with CBS deficiency.
13. ReferencesMudd SH et al. N Engl J Med. 1985 and 9 other papers

1. History

The history of research on sulfur-containing amino acid metabolism begins with the discovery of methionine in the early 20th century. After John Howard Mueller first isolated methionine in 1922, Vincent du Vigneaud in 1932 systematically elucidated the sulfur metabolic pathway and showed that methionine is a precursor of cystine. The concept was established that this pathway proceeds in the order methionine → S-adenosylmethionine (SAM) → S-adenosylhomocysteine (SAH) → homocysteine → cystathionine → cysteine.

In 1955, Gerritsen and Waisman first described a patient with intellectual disability and abnormally high urinary excretion of homocystine, establishing the clinical concept of homocystinuria. In 1963, Mudd, Finkelstein and others biochemically demonstrated that the cause of this disease is deficiency of cystathionine β-synthase (CBS), and in the same year Carson and Neill independently identified CBS deficiency. The four clinical features seen in CBS deficiency patients, namely Marfanoid skeletal abnormalities, ectopia lentis, intellectual disability and thrombosis, were systematically described in the 1960s.

In 1966, an observation was reported that high-dose pyridoxine (vitamin B6) normalizes homocysteine in some CBS deficiency patients, giving rise to the concept of dividing CBS deficiency into pyridoxine-responsive and non-responsive forms. This later became a core criterion for treatment strategy. In the 1970s, methionine adenosyltransferase (MAT I/III) deficiency was described, and it was confirmed that hypermethioninemia mostly follows a benign clinical course. Cystathioninuria was shown to be caused by cystathionase (CTH) deficiency and also to be mostly benign.

In a 1988 study by Klaus Pomaier (Kauwe) et al., the 677C>T polymorphism of the MTHFR (methylenetetrahydrofolate reductase) gene attracted attention for causing a thermolabile enzyme and for being associated, in homozygous (TT) individuals, with mild hyperhomocysteinemia and increased risk of cardiovascular disease. In the 1990s, newborn screening programs based on tandem mass spectrometry (MS/MS) were introduced, making simultaneous measurement of blood methionine and homocystine possible and enabling early diagnosis. In Korea, methionine measurement has been included in expanded newborn screening since 2005, enabling early detection of CBS deficiency and MAT deficiency. With advances in molecular genetic technology since the 2000s, variants in many genes related to sulfur amino acid metabolism, including CBS, CTH, MAT1A, GNMT and MTHFR, have been systematically classified.


2. Causes

Other sulfur-bearing amino acid disorders are a heterogeneous group of diseases caused by deficiency or reduced function of several enzymes in the sulfur amino acid metabolic pathway from methionine to cysteine. Normally, methionine is converted to S-adenosylmethionine (SAM), used in various methylation reactions (DNA, RNA, protein and lipid methylation), becomes S-adenosylhomocysteine (SAH), and SAH is converted to homocysteine. Homocysteine is either recycled to methionine through the folate- and B12-dependent remethylation pathway (MTHFR, MTR, MTRR) or converted to cystathionine (transsulfuration) by pyridoxal phosphate (PLP, vitamin B6)–dependent CBS and then degraded by CTH into cysteine and α-ketobutyric acid.

Cystathionine β-synthase (CBS) deficiency is the cause of classical homocystinuria and is caused by variants of the CBS gene (21q22.3). More than 300 pathogenic variants are registered, and the most common variants are p.I278T (pyridoxine-responsive) and p.G307S (non-responsive). When CBS is deficient, homocysteine cannot be converted to cystathionine, and homocysteine and homocystine accumulate markedly in plasma and urine. Methionine also rises secondarily.

Methionine adenosyltransferase I/III (MAT I/III) deficiency is caused by variants of the MAT1A gene (10q22); the enzyme that converts methionine to SAM in the liver is deficient, and plasma methionine rises markedly (hypermethioninemia). It is mostly asymptomatic, but neurological or liver abnormalities accompany it in some.

Cystathionase (CTH) deficiency is caused by variants of the CTH gene (1p31.1); conversion of cystathionine to cysteine is blocked, and cystathionine is excreted excessively in urine (cystathioninuria). It is generally regarded as a benign metabolic abnormality without clinical symptoms.

MTHFR deficiency is caused by variants of the MTHFR gene (1p36.3); the enzyme that reduces 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate is deficient, remethylation of homocysteine is blocked and homocysteine accumulates. Severe MTHFR deficiency causes serious symptoms including neurological damage. The common polymorphism 677C>T (homozygous TT) reduces enzyme activity by about 30–40% and can cause mild hyperhomocysteinemia. In addition, deficiency of GNMT (glycine N-methyltransferase), BHMT (betaine-homocysteine methyltransferase), MTR (methionine synthase) and MTRR (methionine synthase reductase) also causes abnormal sulfur amino acid metabolism.


3. Genetics

Other sulfur-bearing amino acid disorders are caused by variants in several genes encoding the related enzymes, and most follow an autosomal recessive mode of inheritance. The major associated genes and their chromosomal locations are as follows: CBS (21q22.3), CTH (1p31.1), MAT1A (10q22.3), MAT2A (2p11.2), GNMT (6p12), BHMT (5q13.1-q15), MTHFR (1p36.3), MTR (1q43), MTRR (5p15.3-p15.2). Among these, the MTHFR 677C>T and 1298A>C polymorphisms occupy a distinctive position: unlike complete deficiency variants (rare inherited rare diseases), they are common reduced-function polymorphisms associated with mild homocysteine elevation in the heterozygous or homozygous state.

The CBS gene is located on the long arm of chromosome 21 and is composed of 28 exons. Human CBS has a tetrameric structure composed of 551 amino acids, and each subunit has a pyridoxal phosphate (PLP) cofactor and a heme-binding site. The N-terminal heme-binding domain, which accounts for about 30–40% of CBS activity, has a regulatory function that senses redox state. Variants affecting PLP binding form the molecular basis of the B6-responsive form, in which enzyme function is partially restored by pyridoxine supplementation. The MAT1A gene is located on chromosome 10 and encodes MAT I (homotetramer) and MAT III (heterodimer), which are mainly expressed in the liver. In MAT deficiency, plasma methionine can rise to tens of times normal.

The 677C>T variant of the MTHFR gene substitutes valine for alanine (p.Ala222Val), causing thermolability of the enzyme. The frequency of homozygous (TT) individuals differs by ethnicity and is reported as 10–15% in Caucasians, about 9–12% in Koreans and up to 25% in Mexicans. When folate status is good, homozygous TT may not cause a clinically significant rise in homocysteine, but in folate deficiency homocysteine rises significantly. The MTR gene encodes the cobalamin (vitamin B12)–dependent methionine synthase, and MTRR encodes the reductase that maintains the active form of cobalamin for this enzyme. MTR or MTRR deficiency overlaps with the cobalamin C (cblC)/D/E/G complementation groups and may present as a combined methylmalonic acidemia–hyperhomocysteinemia form.

Genotype–phenotype correlation differs somewhat for each enzyme, but overall, complete deficiency variants (nonsense, frameshift) leave no residual enzyme activity and give a severe phenotype, whereas missense variants leave residual activity and give a varied phenotype from mild to severe. In CBS deficiency, B6 responsiveness is associated with specific variant types (missense variants at or near the PLP-binding site). For family members of an already diagnosed patient, family screening after molecular genetic confirmation of the variant is recommended.


4. General epidemiology

The frequency of other sulfur-bearing amino acid disorders differs by disease. Classical homocystinuria due to CBS deficiency has an incidence of roughly 1 in 200,000–350,000 births in newborn screening–based studies, and higher frequencies have been reported in specific populations such as Ireland (about 1 in 65,000) and Qatar (about 1 in 1,800). In Korea, reports of the exact frequency of CBS deficiency are limited, but it can be estimated from the frequency of elevated methionine in newborn tandem mass spectrometry screening.

The incidence of hypermethioninemia due to MAT I/III deficiency is estimated at about 1 in 50,000–200,000 and is one of the main causes of elevated methionine on newborn screening. In fact, the most common cause of elevated methionine is MAT I/III deficiency, and CBS deficiency is distinguished by the simultaneous elevation of methionine and homocystine. Cystathioninuria due to CTH deficiency is reported at about 1 in 14,000 in traditional newborn screening, a surprisingly common metabolic abnormality, but because it has no clinical symptoms its clinical significance is unclear. Severe MTHFR deficiency is very rare, only a few per million.

In contrast, the frequency of homozygosity (TT) for the MTHFR 677C>T polymorphism in the general population reaches about 10–15% (in Caucasians), making it a common genetic variant. The frequency of 677TT in East Asians including Koreans is reported as about 9–12%. Mild hyperhomocysteinemia (total homocysteine > 15 μmol/L) is observed in about 5–7% of the general adult population and is more common in the elderly, men, smokers, patients with kidney failure and states of folate or B12 deficiency. In cardiovascular risk studies worldwide, hyperhomocysteinemia is regarded as an independent risk factor, and many meta-analyses have been published showing an association with increased risk of stroke, myocardial infarction and deep vein thrombosis.

In Korea, these diseases can be registered under the Rare Disease Act with the E72.1 code (other sulfur-bearing amino acid disorders) for Special Copayment Reduction V117, and copayment reduction benefits are provided upon registration. For CBS deficiency, follow-up at a specialized metabolic clinic after diagnosis of classical homocystinuria is recommended. Methioninemia and cystathioninuria are often clinically asymptomatic, so the registration rate for Special Copayment Reduction is presumed to be low.


5. Pathophysiology

The pathogenesis of sulfur amino acid metabolic disorders is determined by which metabolite accumulates at which step according to the deficiency of a specific enzyme. The core pathway is the flow methionine → SAM (substrate for methylation reactions) → SAH → homocysteine (remethylation or transsulfuration) → cystathionine → cysteine + α-ketobutyric acid.

Pathophysiology of homocysteine accumulation: When plasma total homocysteine (tHcy) rises owing to CBS deficiency or MTHFR/MTR/MTRR deficiency, toxicity arises through various mechanisms. (1) Vascular endothelial damage: Homocysteine induces oxidative stress in vascular endothelial cells (increased ROS generation, decreased endothelial nitric oxide synthase (eNOS) activity), causing endothelial dysfunction. (2) Promotion of thrombotic tendency: It induces a hypercoagulable state through multiple mechanisms such as increased activation of coagulation factors V and X, decreased protein C and S activity, inhibition of tissue plasminogen activator (tPA) and enhanced platelet aggregation. (3) Connective tissue damage: Hyperhomocysteinemia forms abnormal disulfide bonds with fibrillin-1 and disrupts the elastic fiber structure, forming the pathophysiological basis of lens dislocation, Marfanoid skeletal abnormalities and aortic dilatation. (4) Neurotoxicity: Homocysteine and its oxidation product (homocysteic acid) are NMDA receptor agonists and can mediate glutamate excitotoxicity, which is associated with intellectual disability and neurological complications.

Methionine excess accumulation (MAT deficiency): When plasma methionine rises abnormally, an overall imbalance in SAM production may result. In some studies, hepatic steatosis and demyelination abnormalities have been reported in MAT I/III deficiency, but in most cases it is clinically asymptomatic. The view has been put forward that an imbalance in the SAM/SAH ratio may be more important pathophysiologically than hypermethioninemia itself.

Cystathionine accumulation (CTH deficiency): No independent toxic mechanism of cystathionine has been clearly established to date, so it is mostly clinically asymptomatic. Some studies have raised the possibility of an effect on neurodevelopment, but definite evidence is lacking. Pyridoxine supplementation can enhance enzyme activity and reduce cystathioninuria.

Methylation deficiency (MTHFR/MTR deficiency): When the supply of 5-methyltetrahydrofolate (5-MTHF) decreases, remethylation of homocysteine to methionine is reduced, and the following occur in combination: (1) homocysteine accumulation, (2) a general decrease in methylation reactions due to decreased SAM synthesis (DNA hypomethylation, impaired neurotransmitter synthesis), and (3) the folate trap — the tetrahydrofolate form is blocked, also inhibiting other folate metabolic reactions.


6. Symptoms

The spectrum of symptoms of other sulfur-bearing amino acid disorders is very varied depending on the deficient enzyme. It forms a continuous spectrum from completely asymptomatic cases (cystathioninuria, simple MAT deficiency) to severe multi-organ morbidity (CBS deficiency).

CBS deficiency (classical homocystinuria): When untreated, a characteristic tetrad of clinical features appears. ① Ophthalmologic abnormalities: Downward lens dislocation (ectopia lentis downward) occurs in more than 80%, and the risks of myopia, glaucoma and retinal detachment also increase. ② Skeletal abnormalities: A Marfan syndrome–like body habitus (tall, thin build, arachnodactyly, scoliosis, pectus excavatum, flat feet) appears. Osteoporosis accompanies it, and the risk of pathological fracture also increases. ③ Intellectual disability and neuropsychiatric symptoms: When untreated, progressive intellectual disability occurs in about 50%, and seizures and psychiatric symptoms (depression, obsessions, behavioral disorders) are also observed. ④ Thromboembolism: Deep vein thrombosis, pulmonary embolism, coronary thrombosis and stroke may occur before age 30 and are the most common cause of death in untreated CBS deficiency. In the pyridoxine non-responsive form, symptoms appear earlier and more severely.

Hyperhomocysteinemia (MTHFR deficiency, etc.): Severe MTHFR deficiency causes seizures, developmental delay, gait disturbance and psychiatric symptoms (schizophrenia-like symptoms) from infancy. Mild to moderate hyperhomocysteinemia (due to mild MTHFR variants, folate/B12 deficiency, kidney failure, etc.) is associated in adults with increased risk of early myocardial infarction, stroke, deep vein thrombosis, and preeclampsia, placental insufficiency and recurrent miscarriage during pregnancy.

Methioninemia (MAT I/III deficiency): Mostly asymptomatic. In severe cases, a cabbage-like odor on breathing (methyl mercaptan, a methionine metabolite), neurological symptoms (demyelination abnormalities → gait abnormality, cognitive decline) and liver abnormalities (hepatic steatosis, hepatomegaly) may rarely occur. Elevated methionine on newborn screening is the main route by which MAT deficiency is discovered.

Cystathioninuria (CTH deficiency): Generally there are no clinical symptoms. An association with intellectual disability was raised in the past, but it is now assessed to have been a selection bias due to incidental discovery. High-dose pyridoxine can markedly reduce urinary cystathionine excretion, but the evidence of clinical benefit is unclear.


7. Signs

The physical signs and laboratory findings of other sulfur-bearing amino acid disorders vary depending on the causative enzyme.

Ophthalmologic signs of CBS deficiency: On slit-lamp examination, a lens dislocated inferomedially is characteristic (in Marfan syndrome the lens is dislocated upward). As the dislocation progresses, the pupil becomes irregular and visual acuity declines. Myopia (sometimes high myopia), corneal abnormalities, corneal endothelial damage, glaucoma and retinal detachment may accompany it.

Skeletal signs: Increased arm span/height ratio, increased lower segment/upper segment ratio, wrist and thumb signs (Steinberg sign: the thumb protrudes beyond the clenched fist), arachnodactyly, pectus excavatum or pectus carinatum, scoliosis, and joint laxity or hyperextensibility are observed. Low bone density is confirmed on bone mineral density (DEXA) testing. These findings need to be differentiated from Marfan syndrome, connective tissue dysplasia and others.

Signs of thrombosis: When findings of lower-limb deep vein thrombosis (ankle and calf tenderness, swelling, erythema, Homan's sign), pulmonary embolism (chest pain, dyspnea, tachycardia), stroke (hemiparesis, aphasia) or coronary thrombosis (chest pain, ECG abnormalities) occur in a young patient, a sulfur amino acid metabolic disorder should be suspected. Recurrent thrombosis or arterial or venous thrombosis before age 30 must be evaluated with testing for congenital thrombophilia (including hyperhomocysteinemia).

Biochemical findings: Measurement of plasma total homocysteine (tHcy) is key. In CBS deficiency, tHcy is markedly elevated to 100–500 μmol/L or higher (normal < 15 μmol/L), and homocystine is detected in urine. Plasma methionine is also elevated. In MAT deficiency, plasma methionine is markedly elevated but tHcy is normal or mildly elevated. In cystathioninuria, plasma and urine cystathionine are elevated but other indicators are usually normal. Uric acid crystals (urine nitroprusside test, Brand test) may give a positive reaction, reacting to the presence of cystine or homocystine.


8. Screening

The main screening methods for early detection of other sulfur-bearing amino acid disorders are divided into newborn screening and biochemical testing in high-risk groups.

Newborn screening (tandem mass spectrometry, MS/MS): In many countries including Korea, as part of expanded newborn screening, amino acids such as methionine and homocystine are measured by tandem mass spectrometry in dried blood spots (DBS) collected 48–72 hours after birth. Elevated methionine is the main screening indicator for MAT I/III deficiency or CBS deficiency (when homocystine is also elevated). Cystathioninuria is found by measurement of urine cystathionine or plasma amino acid analysis. In some cases of CBS deficiency, methionine is normal in the neonatal period and may be missed by screening, so measurement of plasma tHcy is necessary when clinically suspected.

High-risk group screening: In patients with early thromboembolism of unknown cause (age 30 or younger), recurrent stroke, coronary artery disease, lens dislocation of unknown cause, or intellectual disability + Marfan-like habitus, fasting plasma tHcy should be measured to screen for hyperhomocysteinemia. When necessary, a methionine loading test can differentiate those with a normal baseline test, including heterozygous carriers. For mothers with pregnancy complications (recurrent miscarriage, preeclampsia), assessment of plasma tHcy and folate and B12 status is also recommended.

Family screening: In siblings of patients with confirmed CBS deficiency or another sulfur amino acid disorder, plasma amino acid analysis and tHcy measurement are performed regardless of the newborn screening result. When a molecular genetic variant has been identified, targeted genetic testing identifies family carriers and genetic counseling is provided.


9. Diagnosis

Definitive diagnosis of other sulfur-bearing amino acid disorders is made through a stepwise approach of biochemical testing, enzyme activity measurement and molecular genetic analysis.

Measurement of plasma total homocysteine (tHcy): tHcy is measured in fasting (4 hours or more) plasma by high-performance liquid chromatography (HPLC) or immunoassay. The normal range is 5–15 μmol/L, and 30 μmol/L or higher is classified as moderate and 100 μmol/L or higher as severe hyperhomocysteinemia. In CBS deficiency it usually far exceeds 100 μmol/L. Folate, B12, B6 and kidney function are evaluated together before measurement to exclude causes of secondary hyperhomocysteinemia.

Plasma amino acid analysis: Sulfur amino acids such as methionine, cystathionine, homocystine, cystine and cysteine are quantified by ion-exchange chromatography or LC-MS/MS. The patterns confirmed are simultaneous elevation of methionine and homocystine in CBS deficiency, elevation of methionine alone in MAT deficiency, and elevation of cystathionine in CTH deficiency.

Urine organic acid and amino acid analysis: Abnormal metabolites are identified by qualitative (nitroprusside reaction, Brand test) and quantitative urine homocystine testing and urine amino acid chromatography. Urine total homocystine is markedly increased in CBS deficiency.

Pyridoxine challenge test: After confirmation of CBS deficiency and before treatment, high-dose pyridoxine (200–1,000 mg/day) is given for several weeks and the response of tHcy is checked. If tHcy decreases by 50% or more or normalizes, the patient is classified as pyridoxine-responsive (B6-responsive) and this is reflected in the treatment plan. Pyridoxine responsiveness is an important indicator for predicting course and prognosis.

Enzyme activity measurement: CBS activity can be measured through liver tissue biopsy or cultured skin fibroblasts. CTH activity can also be measured in liver tissue. MAT I/III activity is measured in red blood cells or the liver. Enzyme activity measurement is useful for diagnostic confirmation in patients without an identified variant.

Genetic testing: Pathogenic variants are confirmed by gene panel NGS (next-generation sequencing) of CBS, CTH, MAT1A, MTHFR, MTR, MTRR and others. Variant confirmation is used for definitive diagnosis, prognosis prediction (B6 responsiveness) and family genetic counseling. Genotyping for the MTHFR 677C>T and 1298A>C polymorphisms is used to assess genetic predisposition to mild hyperhomocysteinemia.


10. Treatment

Treatment of other sulfur-bearing amino acid disorders requires an individualized approach according to the causative enzyme and disease severity. CBS deficiency (classical homocystinuria) is the most actively treated, and for other sulfur amino acid disorders conservative or supportive treatment is given according to the clinical situation.

Pyridoxine (vitamin B6) — B6-responsive CBS deficiency: About 40–50% of CBS deficiency responds to high-dose pyridoxine (adults 200–750 mg/day, children weight-based dose), with plasma tHcy markedly decreasing or normalizing. Pyridoxine supplies PLP, the cofactor of CBS, to maximize residual enzyme activity. In B6-responsive patients, long-term pyridoxine treatment has been reported to significantly prevent major complications such as thrombotic complications, intellectual disability and lens dislocation. Long-term high-dose pyridoxine carries a risk of peripheral neuropathy (paresthesia), so monitoring of nerve function is needed.

Dietary management — low-methionine diet: In B6 non-responsive CBS deficiency, plasma methionine and homocysteine levels are kept within the target range with a methionine-restricted diet (restriction of natural protein intake + supplementation with a methionine-free amino acid formula). Cystine is an essential amino acid in CBS deficiency, so cystine should be supplemented in the diet. Dietary management started early (in the neonatal period) is most effective for neurodevelopment and thrombosis prevention.

Betaine: Betaine (trimethylglycine) acts as a methyl donor in the reaction that remethylates homocysteine to methionine via the BHMT pathway, lowering plasma tHcy. It is used as adjunctive treatment of CBS deficiency and in B6 non-responsive patients or those with poor dietary control. Oral dose for adults is 6–20 g/day. A rare complication of cerebral edema has been reported, so caution is needed.

Folate, vitamin B12, vitamin B6 — hyperhomocysteinemia: In hyperhomocysteinemia due to MTHFR deficiency, MTR/MTRR deficiency or nutritional deficiency, supplementation with folate (0.4–5 mg/day), vitamin B12 (cobalamin) and vitamin B6 effectively lowers tHcy. In MTHFR 677TT homozygous individuals, tHcy can be normalized with adequate folate intake. In severe MTHFR deficiency, direct supplementation with 5-methyltetrahydrofolate (5-MTHF) combined with betaine is used.

Thrombosis prevention and treatment: When thrombosis occurs in CBS deficiency, anticoagulant treatment (low-molecular-weight heparin, warfarin) is given as standard. Prophylactic anticoagulation is considered in high-risk situations for thrombosis such as the perioperative period and prolonged bed rest. Low-dose aspirin as an adjunct is also recommended in some patients. Oral contraceptives and hormone replacement therapy in women with CBS deficiency further increase thrombotic risk and are in principle contraindicated.

MAT I/III deficiency — low-methionine diet: A methionine-restricted diet is considered when plasma methionine is very high (> 800 μmol/L) or neurological symptoms accompany it. In asymptomatic simple methioninemia, observation alone is often sufficient. In cystathioninuria, pyridoxine supplementation reduces urinary cystathionine, but because evidence of clinical benefit has not been established, some hold the view that routine treatment is not recommended.


11. Prognosis

The prognosis of other sulfur-bearing amino acid disorders varies greatly according to the causative enzyme, severity and timing of treatment initiation. Overall, patients who receive early diagnosis and active treatment can greatly reduce complications, whereas untreated or late-diagnosed patients may experience severe thrombotic and neurological complications.

Prognosis of CBS deficiency: The pyridoxine-responsive form has a generally good prognosis, with markedly reduced rates of intellectual disability, lens dislocation and thromboembolism with early high-dose pyridoxine treatment. An international collaborative study (HCU Collaborative) reported that the incidence of thrombosis by age 30 in early-treated patients was less than one-tenth that in the untreated group. In the pyridoxine non-responsive form as well, prognosis is greatly improved when dietary management combined with betaine treatment is started from the neonatal period. The main prognostic factors are (1) pyridoxine responsiveness, (2) age at start of treatment and (3) degree of control of plasma tHcy.

In untreated CBS deficiency patients, older natural history studies reported that lens dislocation occurs in about 50% before age 15, thromboembolism in about 50% before age 30, and thrombosis-related death in about 25% by age 50. Intellectual disability (mean IQ about 64) was also common when untreated. However, now that newborn screening and early treatment have become universal, these natural history data do not reflect the actual prognosis of patients.

Prognosis of hyperhomocysteinemia: Severe MTHFR deficiency (complete deficiency) is accompanied by infantile-onset neurological symptoms, developmental delay and thrombotic complications, and even with aggressive supplementation therapy (folate derivatives, betaine) complete normalization is difficult and the long-term prognosis may be poor. In mild hyperhomocysteinemia (based on the MTHFR 677TT polymorphism or nutritional deficiency), reduced cardiovascular risk is expected if folate and B12 supplementation normalize tHcy, but in large randomized clinical trials (VISP, HOPE-2, SEARCH, etc.) the effect of preventing major cardiovascular events was unclear despite lowering of tHcy. This reflects the controversy over whether hyperhomocysteinemia is a cause or a result (marker) of vascular damage.

Prognosis of methioninemia and cystathioninuria: Most of these diseases are clinically asymptomatic, with normal life expectancy and quality of life maintained. Cases of MAT I/III deficiency accompanied by neurological symptoms are rare, but dietary management and monitoring are needed. In these diseases, excessive dietary restriction may adversely affect growth and development, so expert judgment is needed.


12. Prevention

Prevention of other sulfur-bearing amino acid disorders is divided into early diagnosis by newborn screening, achievement of biochemical targets to prevent complications, and genetic counseling.

Newborn screening and early treatment: The most effective preventive strategy is to detect CBS deficiency and MAT deficiency within days of birth through expanded newborn screening (tandem MS/MS) and to start treatment before symptoms appear. Early pyridoxine treatment or dietary management can markedly reduce the occurrence of intellectual disability, lens dislocation and thrombotic complications. In cystathioninuria and simple methioninemia, even when the screening result is abnormal, clinical symptoms are often not caused, so close observation is more appropriate than unnecessary treatment.

Folate and vitamin supplementation: Folate intake (0.4–1 mg/day) before pregnancy and in early pregnancy contributes to preventing hyperhomocysteinemia in pregnant women in addition to preventing neural tube defects. In adults with folate deficiency, vitamin B12 deficiency or B6 deficiency, correcting these lowers tHcy and can reduce thrombotic and cardiovascular risk. In MTHFR 677TT homozygous individuals, adequate folate intake can prevent a rise in tHcy.

Genetic counseling and family screening: Parents (carriers) and siblings of CBS deficiency patients are recommended to have molecular genetic testing along with genetic counseling. Carrier couples can determine whether the fetus is affected by prenatal diagnosis (CVS or amniocentesis) in the next pregnancy. Preimplantation genetic testing (PGT) can be used as a way to prevent implantation of affected embryos.

Management of thrombotic risk: Patients with CBS deficiency should have a prophylactic anticoagulation plan prepared in advance for high-risk thrombotic situations (surgery, long-distance travel, pregnancy, delivery). Women with CBS deficiency are advised to use progesterone-only or nonhormonal contraception instead of estrogen-containing oral contraceptives. For surgery in CBS deficiency patients, multidisciplinary consultation among anesthesiology, hematology and metabolic medicine is needed.


13. References

  1. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37(1):1-31. PMID: 3872065.

  2. Morris AA, Kozich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis. 2017;40(1):49-74. DOI: 10.1007/s10545-016-9979-0. PMID: 27778219.

  3. Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J Inherit Metab Dis. 2011;34(1):75-81. DOI: 10.1007/s10545-010-9177-4. PMID: 20927582.

  4. Huemer M, Kozich V, Rinaldo P, et al. Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines. J Inherit Metab Dis. 2015;38(6):1007-1019. DOI: 10.1007/s10545-015-9830-z. PMID: 25762406.

  5. Födinger M, Hörl WH, Sunder-Plassmann G. Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol. 2000;13(1):20-33. PMID: 10720211.

  6. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31-62. DOI: 10.1146/annurev.med.49.1.31. PMID: 9509248.

  7. Kraus JP, Janosík M, Kozich V, et al. Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat. 1999;13(5):362-375. DOI: 10.1002/humu.4. PMID: 10220142.

  8. Barić I. Inherited disorders in the conversion of methionine to homocysteine. J Inherit Metab Dis. 2009;32(4):459-471. DOI: 10.1007/s10545-009-1146-4. PMID: 19499363.

  9. Skovby F, Gaustadnes M, Mudd SH. A revisit to the natural history of homocystinuria due to cystathionine beta-synthase deficiency. Mol Genet Metab. 2010;99(1):1-3. DOI: 10.1016/j.ymgme.2009.09.009. PMID: 19800260.

  10. Lee HK, Park WJ, Lee YJ, et al. Newborn screening for amino acid disorders in Korea: metabolic profiles and outcomes. J Korean Med Sci. 2021;36(20):e143. DOI: 10.3346/jkms.2021.36.e143. PMID: 34013691.